AVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law Firm

Core Insights - AVITA Medical, Inc. is under investigation for possible securities fraud, with a potential class action being considered for affected investors [1][2] - The company's second quarter 2025 financial results revealed a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted demand [3] - Following the announcement of the backlog, AVITA's share price dropped approximately 21%, from $5.38 to $4.25 [4] Financial Performance - AVITA reported a six-month backlog in unpaid provider claims for Recell procedures, which was attributed to issues with pricing and claim adjudication by contractors from the Centers for Medicare & Medicaid Services [3] - The backlog led to reduced utilization of the Recell product during the first half of 2025, indicating a direct impact on the company's financial performance [3] Market Reaction - The announcement of the backlog and its implications resulted in a significant decline in AVITA's stock price, reflecting investor concerns over the company's operational challenges [4]